Insider Trading March 12, 2026

AdaptHealth insider increases stake with $19.9 million stock purchases

Richard M. Cashin Jr. adds more than 2 million shares as company reports mixed fourth-quarter results

By Hana Yamamoto AHCO
AdaptHealth insider increases stake with $19.9 million stock purchases
AHCO

Richard M. Cashin Jr., a 10% owner of AdaptHealth Corp (NASDAQ:AHCO), acquired 2,046,691 shares between March 10 and March 12, 2026, for roughly $19.9 million. The purchases were executed in multiple transactions at prices between $9.7281 and $9.7299 per share. The stock has been flagged by InvestingPro analysis as potentially undervalued, noting a high shareholder yield and a 17% free cash flow yield. AdaptHealth recently reported fourth-quarter 2025 results that missed EPS expectations while topping revenue estimates, and analysts have adjusted price targets and commentary in response.

Key Points

  • Insider activity: Richard M. Cashin Jr. purchased 2,046,691 shares of AHCO between March 10-12, 2026, for about $19.9 million, increasing his indirect holding to 15,864,871 shares - impacts investor perception in the healthcare and medical equipment sectors.
  • Valuation signals: InvestingPro analysis suggests AHCO may be undervalued, citing a high shareholder yield and a 17% free cash flow yield - relevant to equity valuation and investment research communities.
  • Mixed fundamentals: AdaptHealth’s Q4 2025 results showed an EPS miss (-$0.76 vs. $0.36 expected) while revenue exceeded estimates ($846.3M vs. $832.5M), prompting analyst price-target adjustments and continued scrutiny from the healthcare coverage desks.

Richard M. Cashin Jr., who owns a 10% stake in AdaptHealth Corp (NASDAQ:AHCO), has substantially increased his indirect holdings in the home medical equipment supplier. Between March 10 and March 12, 2026, Cashin purchased a total of 2,046,691 shares of AdaptHealth common stock for an aggregate cost of approximately $19,912,147.

The transactions were executed across three days at prices narrowly clustered between $9.7281 and $9.7299 per share. On March 10, Cashin acquired 820,528 shares; on March 11 he purchased 536,827 shares; and on March 12 he added 689,336 shares. Following these buys, his indirect ownership of AdaptHealth common stock stands at 15,864,871 shares.

InvestingPro’s analysis, cited in company transaction reporting, characterizes the stock as currently undervalued, pointing to a high shareholder yield and a free cash flow yield of 17% as metrics supporting that view. The update also notes that additional valuation detail and ProTips are available in a dedicated Pro Research Report on InvestingPro.


These insider purchases come amid a mixed quarterly financial report for AdaptHealth. The company’s fourth-quarter 2025 earnings per share came in at -$0.76, falling short of the $0.36 consensus and producing a -311.11% surprise versus expectations. Revenue for the quarter totaled $846.3 million, modestly above the $832.5 million forecast by about 1.66%.

Analysts have reacted to the results and forward-looking commentary. RBC Capital retained an Outperform rating on AdaptHealth shares and maintained a $13.00 price target, noting that a recent share-price decline reflected weaker-than-expected fourth-quarter outcomes and guidance that the firm characterized as challenging for 2026. Leerink Partners trimmed its price target to $12.00 from $13.00 while also keeping an Outperform rating, citing progress in the company’s initiatives despite the noisy quarter.

The combination of significant insider buying and a quarter that missed EPS but beat revenue expectations highlights the divergent signals confronting investors assessing AdaptHealth. Cashin’s purchases increase his indirect stake and demonstrate continued insider activity, while the company’s reported metrics and analyst adjustments frame the near-term market narrative.


Summary

  • Richard M. Cashin Jr. acquired 2,046,691 AdaptHealth shares from March 10-12, 2026, for roughly $19.9 million.
  • Purchases occurred at prices between $9.7281 and $9.7299 per share; Cashin now indirectly holds 15,864,871 shares.
  • AdaptHealth reported Q4 2025 EPS of -$0.76 versus an expected $0.36, with revenue of $846.3 million beating the $832.5 million estimate.
  • InvestingPro flagged the stock as potentially undervalued, citing a high shareholder yield and a 17% free cash flow yield.
  • RBC Capital and Leerink Partners maintain Outperform ratings, with price targets set at $13.00 and $12.00 respectively.

Risks

  • Earnings volatility - AdaptHealth posted a significant EPS shortfall in Q4 2025, which could continue to weigh on investor confidence in the healthcare equipment and services segment.
  • Guidance uncertainty - Analysts noted challenging guidance for 2026, a factor that may affect valuation and investor sentiment across healthcare-related equities.
  • Market reaction - Recent share-price pressure attributed to weaker-than-expected results could introduce short-term liquidity and price-risk for shareholders in the medical equipment and healthcare services markets.

More from Insider Trading

Palladyne AI CFO Disposes $57,749 in Stock; Company Posts Strong Revenue Growth but Remains Loss-Making Mar 12, 2026 Palladyne AI Chief Legal Officer Disposes $51,355 in Stock; Executive Also Receives RSUs Mar 12, 2026 Palladyne AI CTO Disposes $97.7K in Stock as Shares Remain Volatile Mar 12, 2026 Patrick Industries Director Increases Stake with $1.13M Purchase Mar 12, 2026 Figure Technology Director Disposes $7.29M in Class A Shares Mar 12, 2026